Aclaris Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -46.0% | -46.0% | -36.2% |
| FY2022 | -44.0% | -44.0% | -34.1% |
| FY2023 | -56.3% | -56.3% | -44.8% |
| FY2024 | -84.9% | -84.9% | -59.9% |
| FY2025 | -63.0% | -63.0% | -40.5% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -46.0% | -46.0% | -36.2% |
| FY2022 | -44.0% | -44.0% | -34.1% |
| FY2023 | -56.3% | -56.3% | -44.8% |
| FY2024 | -84.9% | -84.9% | -59.9% |
| FY2025 | -63.0% | -63.0% | -40.5% |